82
Participants
Start Date
January 4, 2006
Primary Completion Date
June 16, 2010
Study Completion Date
June 16, 2010
Antihemophilic factor, recombinant, manufactured protein-free
Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
Antihemophilic factor, recombinant, manufactured protein-free
PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
Los Angeles
Chicago
Indianapolis
Minneapolis
New York
Oklahoma City
Portland
Hershey
Seattle
Vienna
Brno
Prague
Athens
Budapest
Debrecen
Pécs
Szeged
Szombathely
Florence
Milan
Gdansk
Krakow
Lublin
Warsaw
Wroclaw
Moscow
Ljubljana
Cardiff
Nottingham
Baxalta now part of Shire
INDUSTRY